Humana Inc

Humana’s March 2026 strategy blends board realignment, CGM adoption and AI to boost Medicare Advantage profits, cut costs, and win CMS bonus payments.

Humana’s recent stock rebound, stable P/E, and focus on coordinated care and provider stability in Medicare Advantage signal resilience and growth potential for investors, clinicians, and patients alike.

Humana’s Q4 beats expectations but 2026 guidance falls short, sparking concerns. Learn how the company’s primary‑care expansion, MaxHealth deal, and margin pressures shape its future.

Explore how Morgan Stanley’s downgrade of Humana signals Medicare rate risks and market dynamics—why investors should watch cost‑control and digital growth for future earnings.

Explore how Humana’s recent institutional buys, share‑price trends and value‑based care expansion signal its strategic health‑care role—insights for investors and industry leaders.

Humana’s stock fell ~9% in 2025‑26, driven by Medicare policy shifts and cost pressures. Discover how institutional trades, PBM risks, and digital opportunities shape the insurer’s future.

Humana’s new $120 M Defense Health Agency contract, nursing‑leadership partnership, and $5 M social‑determinants push aim to boost revenue, workforce, and community health.

Humana’s latest partnership with Nurses on Boards, new community outreach data, leadership shifts, and credit reaffirmation highlight the company’s focus on workforce development, social responsibility, and financial stability to navigate evolving m…

Humana explores a partnership with Mark Cuban’s Cost‑Plus Drugs to offer direct‑to‑patient, transparent‑pricing mail‑order pharmacy services for Medicare members.

Humana Inc. has secured a favorable ruling in a Medicare Advantage lawsuit, reinforcing its compliance posture and stability of revenue streams, while also continuing to invest in innovation and precision healthcare solutions.